Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma

Summary

This phase I/II trial studies the side effects and best dose of Visudyne (liposomal verteporfin) and to see how well it works in treating patients with high grade EGFR-mutated glioblastoma that has come back (recurrent). Visudyne is FDA approved in combination with light to treat eye diseases. In this study we use Visudyne by itself like chemotherapy to kill tumor cells which may be sensitive to verteporfin.

Timeline

Start

2021-01-15

Primary completion

2025-08-15

Completion

2025-08-15

Drugs

Indications